Merck Manuals Survey: 88 Percent of Nurse Practitioners Spend at Least Half of Appointment Times on Patient Education

95 percent of NPs believe their patients attempt to diagnose themselves prior to appointments

KENILWORTH, N.J., July 26, 2017 /PRNewswire/ -- Nurse practitioners play a crucial role in helping patients decode medical information, according to the findings of a Merck Manuals survey released today. The survey of 210 NPs, conducted at a recent medical conference, revealed that most (88 percent) believe they spend at least half of appointment times educating patients on diagnoses, treatments and prescriptions.

A majority of NPs (78 percent) do prefer their patients do research ahead of appointments. However, many patients tend to turn that research into assumed diagnoses. Ninety-five percent of NPs say most of their patients attempt to diagnose themselves prior to appointments.

This is particularly concerning given that when asked to characterize the health literacy of patients, nearly half (45 percent) said their patients' lack of understanding is a barrier to maintaining their health. Forty-eight percent said their patients understand enough to follow basic treatment instructions, and just seven percent said patients are knowledgeable, with specific ideas about their treatment.

"Today, effective patient care requires NPs to help their patients cut through the clutter of medical misinformation," said Dr. Robert S. Porter, M.D., Merck Manuals Editor-in-Chief. "A little bit of research before an appointment can help educate patients, but only if they reference a credible source and plan to discuss their findings with their healthcare professional."

According to the survey, NPs believe their patients prepare for appointments in several ways:

  • Doing online research (59 percent);
  • Talking to a physician/nurse they know (31 percent);
  • Printing materials to bring to the appointment (10 percent).

But about half (51 percent) say their patients don't prepare for appointments at all.

"Sometimes patients see a commercial on TV and research it, and automatically diagnose themselves with a condition they don't necessarily have. Then they want therapy or treatment that's not appropriate," said Jessica, an NP from Austin, TX, surveyed at the conference. "So one of the biggest challenges is working through the misinformation, and educating them as to why they don't have what they think they have."

When asked about the top factors challenging the nurse practitioner/patient relationship, half of respondents ranked shortened appointment times as the most crucial, followed by low health literacy and increased dependency on paperwork/digital records.

"Physicians and NPs can help their patients prepare to discuss their medical condition and treatment options," Dr. Porter said. "This is especially important as more patients access medical information online. Having a free resource like MerckManuals.com for consumers and professionals allows NPs to quickly share trusted medical information, written in understandable language."

Learn more about the Merck Manuals' mission to make the best medical information freely accessible to 3 billion consumers and healthcare professionals around the world by 2020 at MerckManuals.com.

About The Merck Manuals

First published in 1899 as a small reference book for physicians and pharmacists, The Merck Manual grew in size and scope to become one of the world's most widely used comprehensive medical resources for professionals and consumers. As The Manual evolved, it continually expanded the reach and depth of its offerings to reflect the mission of providing the best medical information to a wide cross-section of users, including medical professionals and students, veterinarians and veterinary students, and consumers. In 2015, The Merck Manual kicked off Global Medical Knowledge 2020, a program to make the best current medical information accessible by up to three billion professionals and patients around the world by 2020. For access to thousands of medical topics with images, videos and a constantly expanding set of resources, visit MerckManuals.com and connect with us on social media:

For Consumers in the U.S. and its territories: Twitter and Facebook
For Professionals in the U.S. and its territories: Twitter and Facebook

Methodology

The survey of 210 nurse practitioners was conducted in June 2017 at a national conference. For details on survey methodology, please contact Jamie Kloss at jamie@gobraithwaite.com.

About Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on TwitterFacebookInstagram, YouTube and LinkedIn.

View original content with multimedia:http://www.prnewswire.com/news-releases/merck-manuals-survey-88-percent-of-nurse-practitioners-spend-at-least-half-of-appointment-times-on-patient-education-300494059.html

SOURCE MerckManuals.com

Sequoia Sciences Receives FDA Fast Track Designation for Vaccine for Urinary Tract Infections Caused by Multidrug-Resistant Bacteria

Non-Antibiotic Treatment Approach May Reduce the Development of Antibiotic Resistance and Promote Antibiotic Stewardship

ST. LOUIS, July 26, 2017 /PRNewswire/ -- Sequoia Sciences announced it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its novel, investigational vaccine designed to treat recurrent urinary tract infections (UTI) caused by multidrug-resistant bacteria. Fast Track Designation expedites the development and review of the vaccine through the U.S. regulatory process.

Sequoia's vaccine is designed to create an immune response preventing bacteria from colonizing the urinary tract, and it recently completed its first clinical trial in women. Of the 67 women enrolled in this first study, 30 had a two-year documented history of recurrent UTI. The vaccine was well-tolerated and generated a strong immune response.1 Based on the results of this first study, initiation of additional studies is ongoing including evaluating Sequoia's vaccine in patients requiring last-line of defense antibiotics. In granting Fast Track status, the FDA acknowledges that recurrent UTI caused by multidrug-resistant bacteria is a serious condition for which there is an unmet medical need.

"If approved, the vaccine could change the standard of care for recurrent UTI," said Gary Eldridge, president and CEO, Sequoia Sciences. "Since UTI are a primary source of sepsis, decreasing recurrent UTI may ultimately drive down rates of hospitalization, sepsis and associated in-hospital mortality."

Recurrent UTI Are Increasing Antibiotic Resistance

Antibiotics are the current standard of care for UTI patients, but repeated antibiotic use in this population contributes to the development of antibiotic resistance. Recurrent UTI patients frequently take daily antibiotics for one to four months or even longer. Each year, approximately 3 million patients in the U.S. and 10 million patients in North America, Europe and Japan experience recurrent UTI.2 It is estimated that about half of these patients have UTI caused by antibiotic-resistant bacteria.3

In a 2010 survey, 83 percent of urologists reported having administered intravenous antibiotics to recurrent UTI patients who were resistant to all available oral antibiotics.4 Antibiotic resistance among UTI patients has continued to increase. The North American Emerging Infections Network reported that about 80 percent of responding infectious disease physicians had treated a UTI caused by the most resistant bacteria, carbapenem-resistant Enterobacteriaceae (CRE).5 Even more alarming, in 2016 CRE among patients in long-term care facilities was found to be more widespread than predicted.6 There are currently no FDA-approved therapies to specifically treat recurrent UTI.

"Many of my patients with multidrug-resistant recurrent urinary tract infections have tried multiple antibiotics for years without success," said Liz D'Antonio, CRNP, director of clinical research Anne Arundel Urology. "A vaccine presents a new approach that could offer new hope for these patients. We eagerly await the results of the next studies as it hopefully moves toward approval."

Antibiotic Resistance — A Global Health Threat

Leading health care organizations, including Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, World Health Organization and Infectious Diseases Society of America (IDSA), have declared that antibiotic resistance is one of the most serious health threats facing the world.7 New rules requiring antibiotic stewardship programs in hospitals emphasize the need to use fewer antibiotics. Sequoia's investigational vaccine, if approved by the FDA, may help reduce the use of antibiotics and address this growing health threat.

About Sequoia Sciences

Sequoia Sciences is a pharmaceutical company discovering and developing new medicines targeting bacterial infections and cancers. Our pipeline includes a vaccine for the treatment and prevention of recurrent urinary tract infections and compounds targeting infection and cancer.

Forward-Looking Statements

Some statements in this news release are, or may be considered forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. Sequoia Sciences cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry.

1 Sequoia Sciences' Annual Report 2016.
2 2014 National Disease and Therapeutic Index (NDTI, IMS Health, Plymouth Meeting, PA). ICD9: 595.0; 595.9; 599.0; 597.8.
3 Sanchez et al. Antibiotic Resistance among Urinary Isolates from Female Outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother. 2016;60(5):2680-3; Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: European Centre for Disease Prevention and Control; 2015.
4 Urologist UTI Survey. Sequoia Sciences, Inc. and HRA Research; 2010.
5 Trevino et al. Perceptions and behaviours of infectious diseases physicians when managing urinary tract infections due to MDR organisms. J Antimicrob Chemother. 2015;70(12):3397-3400.
6 Han et al. Epidemiology of Carbapenem-Resistant Klebsiella Pneumoniae in a Network of Long-Term Acute Care Hospitals. Clinical Infectious Diseases. 2017;64(7):839-44.
7 Ventola CL. The Antibiotic Resistance Crisis: Part 1: Causes and Threats. Pharmacy and Therapeutics. 2015;40(4):277-83; World Health Organization Fact Sheets. [cited 2016 November 3]; Available from: http://www.who.int/mediacentre/factsheets/fs194/en/.

 

View original content:http://www.prnewswire.com/news-releases/sequoia-sciences-receives-fda-fast-track-designation-for-vaccine-for-urinary-tract-infections-caused-by-multidrug-resistant-bacteria-300493148.html

SOURCE Sequoia Sciences

Diplomat Now Dispensing VOSEVI(TM) to Treat Chronic Hepatitis C Virus

The nation's largest independent specialty pharmacy is now dispensing VOSEVI(TM) (sofosbuvir, velpatasvir, and voxilaprevir).

FLINT, Mich., July 26, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) is now dispensing newly approved VOSEVI™ (sofosbuvir/velpatasvir/voxilaprevir) to treat hepatitis C virus infection.

VOSEVI is used to treat all genotypes of chronic hepatitis C virus infection. It is indicated for adults without cirrhosis (liver disease) or with compensated cirrhosis who have previously been treated with a regimen containing an NS5A inhibitor such as EPCLUSA® (sofosbuvir/velpatasvir); HARVONI® (ledipasvir/sofosbuvir); VIEKIRA PAK or VIEKIRA XR (dasabuvir/ombitasvir/paritaprevir/ritonavir); TECHNIVIE (ombitasvir/paritaprevir/ritonavir); ZEPATIER® (elbasvir/grazoprevir); or DAKLINZA (daclatasvir).

VOSEVI is also indicated for chronic hepatitis C infection with genotype 1a or 3 and previous treatment with a regimen containing SOVALDI® (sofosbuvir) without an NS5A inhibitor.

To learn more about Diplomat's hepatitis program, visit diplomat.is/areas-of-excellence/hepatitis.

VOSEVI is a fixed-dose, combination tablet administered once-daily with food for 12 weeks. It contains sofosbuvir and velpatasvir­, as well as the newly approved voxilaprevir.

"Diplomat is proud to expand its therapy offerings to patients who have been diagnosed with chronic hepatitis C," said Paul Urick, president of Diplomat. "Providing an opportunity to treat patients who have failed current treatment options, this combination tablet is a valuable addition to our product offering."

More than 2.7 million Americans have hepatitis C, according to the Centers for Disease Control and Prevention. Hepatitis C infection becomes chronic in approximately 75–85 percent of cases. Unlike many serious diseases, hepatitis C can be cured with treatment.

Hepatitis C causes liver inflammation. Some people with chronic hepatitis C infection develop cirrhosis, in which liver tissue is replaced by scar tissue, eventually preventing the liver from functioning properly.

VOSEVI is manufactured by Gilead Sciences, Inc. For full prescribing information, click here.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) is the nation's largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

CONTACT:
Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is

 

View original content with multimedia:http://www.prnewswire.com/news-releases/diplomat-now-dispensing-vosevi-to-treat-chronic-hepatitis-c-virus-300494212.html

SOURCE Diplomat Pharmacy, Inc.

The Galien Foundation Debuts 2017 Prix Galien USA Nominees in “Best Biotechnology Product,” “Best Pharmaceutical Product,” and “Best Medical Technology” Categories

Winners will be Announced and Recognized by Committee of Distinguished Scientific Leaders on October 26, 2017 at the Prix Galien USA Awards Ceremony

NEW YORK, July 26, 2017 /PRNewswire/ -- The Galien Foundation announced today the 2017 11th Annual Prix Galien USA Award Nominees. Counted among the global health innovation industry's most prized honors, the Prix Galien Award recognizes outstanding biomedical and technology product achievement that improves the human condition.

To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for market within the last five years and demonstrate tremendous potential to impact human health. Sales data are not considered by the nominating committee in their award nominee selection; only science and health impact.

"The 2017 nominees are working each day to ensure a healthier future for the next generation," said Dr. P. Roy Vagelos, chairman, Prix Galien USA Awards Committee, and prior recipient of the Pro Bono Humanum Award. "The selection committee appreciates the unwavering devotion by the teams of researchers, scientists and innovators that have dedicated their lives to such a worthy cause, and we are honored to recognize their achievements."

The Prix Galien USA 2017 nominees include in-market products evaluated in the following categories: "Best Biotechnology Product" – 15 nominees; "Best Pharmaceutical Agent" – 34 nominees, and "Best Medical Technology" – 11 nominees.

Best Biotechnology Product (Nominees)

Alexion Pharmaceuticals Inc.

Kanuma®

Alexion Pharmaceuticals Inc.

Strensiq®

Amgen Inc.

IMLYGIC®

Amgen Inc.

Repatha®

Biogen & Ionis Pharmaceuticals

SPINRAZA™

Boehringer Ingelheim

Praxbind®

Eli Lilly and Company

CYRAMZA®

Eli Lilly and Company

LARTRUVO™

Genentech, a Member of the Roche Group

Kadcyla®

GlaxoSmithKline plc

Benlysta®

Merck & Co., Inc.

Zinplava™

Onyx Pharmaceuticals Inc. & Amgen Inc.

Blincyto®

Pfizer Inc.

Trumenba®

Regeneron and sanofi

PRALUENT®

Sarepta Therapeutics, Inc.

EXONDYS 51™

 

Best Pharmaceutical Agent (Nominees)

AbbVie Inc.

Duopa™

AbbVie Inc.

Technivie™

AbbVie Inc.

Venclexta™

ACADIA Pharmaceuticals Inc.

NUPLAZID®

Allergan, Inc.

Dalvance®

Allergan, Inc.

Kybella®

Allergan, Inc.

Viberzi™

Astellas

Cresemba®

AstraZeneca

Lynparza®

AstraZeneca

Tagrisso®

Boehringer Ingelheim

Jardiance®

Boehringer Ingelheim

OFEV®

Bristol-Myers Squibb Company

Daklinza™

Eisai Inc.

Halaven®

Eisai Inc.

Lenvima®

Endoceutics, Inc.

Intrarosa™

Genentech, a Member of the Roche Group

Alecensa®

Genentech, a Member of the Roche Group

Esbriet®

Gilead

Harvoni®

Helsinn Therapeutics Inc. & Eisai Inc.

Akynzeo®

Iroko Pharmaceuticals, LLC

Vivlodex™

Janssen Pharmaceutical Companies

DARZALEX™

Janssen Pharmaceutical Companies

YONDELIS®

Jazz Pharmaceuticals

Defitelio®

LEO Pharma Inc.

Enstilar®

Merck & Co., Inc.

Zepatier®

Novartis

ZYKADIA®

Otsuka Pharmaceutical Co., Ltd.

Rexulti®

Pfizer Inc.

XELJANZ®

Pfizer Inc. and Astellas

Xtandi®

Shire plc

Xiidra®

The Medicines Company

Orbactiv®

UCB, Inc.

Briviact®

Valeant

Jublia®

 

Best Medical Technology (Nominees)

Abbott

CardioMEMS™ HF System

Allergan, Inc.

Juvederm Volbella® XC

Biosense Webster

The THERMOCOOL SMARTTOUCH®, THERMOCOOL
SMARTTOUCH® Surround Flow Catheters and The CARTO
SMARTTOUCH™ Software Module   

Boston Scientific

SpyGlass DS™ Direct Visualization System

Boston Scientific

WATCHMAN™ Left Atrial Appendage Closure Device

BrainScope Company, Inc.

BrainScope® One

INSIGHTEC

Exablate Neuro

Integra LifeSciences

Omnigraft™ Dermal Regeneration Matrix

Johnson & Johnson - DePuy Synthes

ATTUNE® Knee System

Johnson & Johnson - Ethicon

EVARREST® Fibrin Sealant Patch

Koning Corporation

Koning Breast CT 1000

 

"As the realm of scientific discovery and medical innovation shuttles forward, we were thrilled to see so many high-caliber submissions this year," said Bruno Cohen, chairman of the Galien Foundation.  "Our Foundation is continually impressed by the achievement of the Prix Galien candidates each year, but 2017 has become a benchmark for future years."

The Prix Galien USA Committee is comprised of thirteen renowned leaders from the biomedical industry and academia, including four Nobel Laureates, responsible for evaluating nominees. Winners will be announced during the Prix Galien USA Awards Ceremony on October 26, 2017, at the American Museum of Natural History in New York City.  Registration to attend the 2017 Prix Galien USA Awards Ceremony can be accessed here.

Prix Galien Awards Committee 2017

Pr Richard AXEL,
M.D. Nobel Laureate, Co-director, the Kavli Institute for Brain Science, Columbia University Medical Center, New York

Pr Michael S. BROWN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

Pr Susan DESMOND-HELLMANN,
M.D., M.Ph. Chief Executive Officer of the Bill & Melinda Gates Foundation, Seattle, WA

Pr Laurie GLIMCHER,
M.D. Chief Executive Officer and President, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School

Pr Joseph GOLDSTEIN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

Pr Robert S. LANGER,
M.D. David H. Koch Institute Professor at MIT

Pr Cato T. LAURENCIN,
M.D., Ph.D. University Professor, University of Connecticut, CT

Pr Paul A. MARKS,
M.D. Laboratory Head of Cell Biology Memorial Sloan Kettering Cancer Center, New-York. President Emeritus, MSKCC

Pr Rebecca RICHARDS-KORTUM,
Ph.D. Professor of Bioengineering, Malcolm Gillis University, Houston, TX

Pr Michael ROSENBLATT,
M.D. Chief Medical Officer of Flagship Ventures, Cambridge, MA

Pr Bengt SAMUELSSON, M.D., Ph.D. Nobel Laureate, Former President of Karolinska Institute and Former Chairman of the Nobel Foundation

Pr Marc TESSIER-LAVIGNE,
Ph.D. President, Stanford University, Stanford, CA

Pr P. Roy VAGELOS,
M.D. Retired Chairman and CEO, Merck & Co., Inc. Chairman of the Board, Regeneron Pharmaceuticals, Inc. Committee Chairman

About The Galien Foundation

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

For more information, visit www.galienfoundation.org.

Galien Foundation Media Contact:
Giana Gregga
Finn Partners
312-329-3910
giana.gregga@finnpartners.com

View original content with multimedia:http://www.prnewswire.com/news-releases/the-galien-foundation-debuts-2017-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories-300494168.html

SOURCE The Galien Foundation

The Galien Foundation Debuts 2017 Prix Galien USA Nominees in “Best Biotechnology Product,” “Best Pharmaceutical Product,” and “Best Medical Technology” Categories

Winners will be Announced and Recognized by Committee of Distinguished Scientific Leaders on October 26, 2017 at the Prix Galien USA Awards Ceremony

NEW YORK, July 26, 2017 /PRNewswire/ -- The Galien Foundation announced today the 2017 11th Annual Prix Galien USA Award Nominees. Counted among the global health innovation industry's most prized honors, the Prix Galien Award recognizes outstanding biomedical and technology product achievement that improves the human condition.

To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for market within the last five years and demonstrate tremendous potential to impact human health. Sales data are not considered by the nominating committee in their award nominee selection; only science and health impact.

"The 2017 nominees are working each day to ensure a healthier future for the next generation," said Dr. P. Roy Vagelos, chairman, Prix Galien USA Awards Committee, and prior recipient of the Pro Bono Humanum Award. "The selection committee appreciates the unwavering devotion by the teams of researchers, scientists and innovators that have dedicated their lives to such a worthy cause, and we are honored to recognize their achievements."

The Prix Galien USA 2017 nominees include in-market products evaluated in the following categories: "Best Biotechnology Product" – 15 nominees; "Best Pharmaceutical Agent" – 34 nominees, and "Best Medical Technology" – 11 nominees.

Best Biotechnology Product (Nominees)

Alexion Pharmaceuticals Inc.

Kanuma®

Alexion Pharmaceuticals Inc.

Strensiq®

Amgen Inc.

IMLYGIC®

Amgen Inc.

Repatha®

Biogen & Ionis Pharmaceuticals

SPINRAZA™

Boehringer Ingelheim

Praxbind®

Eli Lilly and Company

CYRAMZA®

Eli Lilly and Company

LARTRUVO™

Genentech, a Member of the Roche Group

Kadcyla®

GlaxoSmithKline plc

Benlysta®

Merck & Co., Inc.

Zinplava™

Onyx Pharmaceuticals Inc. & Amgen Inc.

Blincyto®

Pfizer Inc.

Trumenba®

Regeneron and sanofi

PRALUENT®

Sarepta Therapeutics, Inc.

EXONDYS 51™

 

Best Pharmaceutical Agent (Nominees)

AbbVie Inc.

Duopa™

AbbVie Inc.

Technivie™

AbbVie Inc.

Venclexta™

ACADIA Pharmaceuticals Inc.

NUPLAZID®

Allergan, Inc.

Dalvance®

Allergan, Inc.

Kybella®

Allergan, Inc.

Viberzi™

Astellas

Cresemba®

AstraZeneca

Lynparza®

AstraZeneca

Tagrisso®

Boehringer Ingelheim

Jardiance®

Boehringer Ingelheim

OFEV®

Bristol-Myers Squibb Company

Daklinza™

Eisai Inc.

Halaven®

Eisai Inc.

Lenvima®

Endoceutics, Inc.

Intrarosa™

Genentech, a Member of the Roche Group

Alecensa®

Genentech, a Member of the Roche Group

Esbriet®

Gilead

Harvoni®

Helsinn Therapeutics Inc. & Eisai Inc.

Akynzeo®

Iroko Pharmaceuticals, LLC

Vivlodex™

Janssen Pharmaceutical Companies

DARZALEX™

Janssen Pharmaceutical Companies

YONDELIS®

Jazz Pharmaceuticals

Defitelio®

LEO Pharma Inc.

Enstilar®

Merck & Co., Inc.

Zepatier®

Novartis

ZYKADIA®

Otsuka Pharmaceutical Co., Ltd.

Rexulti®

Pfizer Inc.

XELJANZ®

Pfizer Inc. and Astellas

Xtandi®

Shire plc

Xiidra®

The Medicines Company

Orbactiv®

UCB, Inc.

Briviact®

Valeant

Jublia®

 

Best Medical Technology (Nominees)

Abbott

CardioMEMS™ HF System

Allergan, Inc.

Juvederm Volbella® XC

Biosense Webster

The THERMOCOOL SMARTTOUCH®, THERMOCOOL
SMARTTOUCH® Surround Flow Catheters and The CARTO
SMARTTOUCH™ Software Module   

Boston Scientific

SpyGlass DS™ Direct Visualization System

Boston Scientific

WATCHMAN™ Left Atrial Appendage Closure Device

BrainScope Company, Inc.

BrainScope® One

INSIGHTEC

Exablate Neuro

Integra LifeSciences

Omnigraft™ Dermal Regeneration Matrix

Johnson & Johnson - DePuy Synthes

ATTUNE® Knee System

Johnson & Johnson - Ethicon

EVARREST® Fibrin Sealant Patch

Koning Corporation

Koning Breast CT 1000

 

"As the realm of scientific discovery and medical innovation shuttles forward, we were thrilled to see so many high-caliber submissions this year," said Bruno Cohen, chairman of the Galien Foundation.  "Our Foundation is continually impressed by the achievement of the Prix Galien candidates each year, but 2017 has become a benchmark for future years."

The Prix Galien USA Committee is comprised of thirteen renowned leaders from the biomedical industry and academia, including four Nobel Laureates, responsible for evaluating nominees. Winners will be announced during the Prix Galien USA Awards Ceremony on October 26, 2017, at the American Museum of Natural History in New York City.  Registration to attend the 2017 Prix Galien USA Awards Ceremony can be accessed here.

Prix Galien Awards Committee 2017

Pr Richard AXEL,
M.D. Nobel Laureate, Co-director, the Kavli Institute for Brain Science, Columbia University Medical Center, New York

Pr Michael S. BROWN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

Pr Susan DESMOND-HELLMANN,
M.D., M.Ph. Chief Executive Officer of the Bill & Melinda Gates Foundation, Seattle, WA

Pr Laurie GLIMCHER,
M.D. Chief Executive Officer and President, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School

Pr Joseph GOLDSTEIN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

Pr Robert S. LANGER,
M.D. David H. Koch Institute Professor at MIT

Pr Cato T. LAURENCIN,
M.D., Ph.D. University Professor, University of Connecticut, CT

Pr Paul A. MARKS,
M.D. Laboratory Head of Cell Biology Memorial Sloan Kettering Cancer Center, New-York. President Emeritus, MSKCC

Pr Rebecca RICHARDS-KORTUM,
Ph.D. Professor of Bioengineering, Malcolm Gillis University, Houston, TX

Pr Michael ROSENBLATT,
M.D. Chief Medical Officer of Flagship Ventures, Cambridge, MA

Pr Bengt SAMUELSSON, M.D., Ph.D. Nobel Laureate, Former President of Karolinska Institute and Former Chairman of the Nobel Foundation

Pr Marc TESSIER-LAVIGNE,
Ph.D. President, Stanford University, Stanford, CA

Pr P. Roy VAGELOS,
M.D. Retired Chairman and CEO, Merck & Co., Inc. Chairman of the Board, Regeneron Pharmaceuticals, Inc. Committee Chairman

About The Galien Foundation

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

For more information, visit www.galienfoundation.org.

Galien Foundation Media Contact:
Giana Gregga
Finn Partners
312-329-3910
giana.gregga@finnpartners.com

View original content with multimedia:http://www.prnewswire.com/news-releases/the-galien-foundation-debuts-2017-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories-300494168.html

SOURCE The Galien Foundation

Forge Therapeutics Forms Scientific Advisory Board with World Renowned Antibiotic and Drug Development Experts

SAN DIEGO, July 26, 2017 /PRNewswire/ -- Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, announced today the formation of its Scientific Advisory Board (SAB) with leading experts in microbiology, chemistry and antibiotic drug development.  The Forge SAB will help guide the company's scientific vision and mission to discover and develop novel metalloprotein inhibitors. 

"We are honored that each of these acclaimed researchers and drug developers has agreed to serve on the Forge Scientific Advisory Board," said Zachary A. Zimmerman, CEO of Forge. "Their guidance on our scientific vision will be invaluable as we drive our novel, Gram-negative antibiotic program toward the clinic and identify expansion opportunities for our metalloprotein platform." 

About the Forge SAB

Forge has assembled a strategic advisory board comprised of leading microbiology, chemistry, antibiotic and drug development experts from around the globe. 

  • Michael Barbachyn, Ph.D., co-inventor of the antibiotics linezolid (marketed as Zyvox) and sutezolid, and former director-level contributor to antibacterial discovery at Pharmacia, Pfizer and AstraZeneca.
  • Robert Bonomo, M.D., Chief Medical Service at Louis Stokes Cleveland VA Medical Center, and Professor of Medicine at Case Western Reserve University.
  • Seth Cohen, Ph.D., scientific co-founder of Forge and one of the world's leading authorities on metalloprotein inhibitors; Professor and former Chair of the Department of Chemistry and Biochemistry at the University of California, San Diego.
  • John Rex, M.D., Chief Medical Officer and Director at F2G Ltd. and Chief Strategy Officer at CARB-X, the world's largest public-private partnership devoted to antibacterial preclinical R&D.
  • Karen Joy Shaw, Ph.D., current Chief Scientific Officer of Amplyx Pharmaceuticals and former SVP Biology at Trius Therapeutics leading the microbiology strategy for Tedizolid development; former Antibacterial Team Leader Johnson & Johnson and Schering Plough. 
  • Lynn Silver, Ph.D., was involved in the discovery of the first inhibitors of LpxC, and the development of the antibiotic Invanz at Merck where she held the title of senior investigator.
  • Brad Spellberg, M.D., Chief Medical Officer, LA+USC Medical Center and antibiotic resistance expert.
  • Andrew Tomaras, Ph.D., Vice President and Director of Microbiology at BacterioScan Inc. and former LpxC program leader at Pfizer.
  • Mark Whittaker, D.Phil., SVP Drug Discovery at Evotec and former Director Medicinal Chemistry at British Biotech.

About Forge Therapeutics

Forge Therapeutics is a privately-held biopharmaceutical company developing novel antibiotics to treat multi-drug resistant bacteria, or 'superbugs,' that have ignited a global health epidemic.  With its proprietary chemistry approach, Forge develops small molecule inhibitors targeting metalloenzymes.  Forge's lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and which is essential for bacteria to grow.  Forge has discovered novel small molecule inhibitors of LpxC that are potent in vitro, efficacious in vivo, and effective against drug resistant Gram-negative bacteria 'superbugs.'  To complement its innovative approach to drug discovery, Forge has a capital efficient business model that utilizes a mix of non-dilutive and traditional funding sources to advance its programs, including LpxC.  Forge has formed a strategic alliance with leading drug discovery alliance and development partnership company Evotec AG and has been awarded multiple government awards to address the global 'superbug' epidemic including CARB-X.  In addition, Forge has amassed a rich intellectual property estate on metalloprotein inhibitors to protect its technology and pipeline.  For further information, please visit the company's website www.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.

Forge Company Contact:
Info@ForgeTherapeutics.com

Forge Media Contact:
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243

 

View original content with multimedia:http://www.prnewswire.com/news-releases/forge-therapeutics-forms-scientific-advisory-board-with-world-renowned-antibiotic-and-drug-development-experts-300494171.html

SOURCE Forge Therapeutics, Inc.

Innovative PBM Introduces Pharmacogenetics Offering

BeneCard PBF Launches BenePrecise to Eliminate Trial and Error in Finding Medications That Work

MECHANICSBURG, Pa., July 26, 2017 /PRNewswire/ -- BeneCard PBF, a leader in providing clinical solutions that address the crisis of rising drug costs, has taken a step toward more efficient, personalized clinical care for members through its BenePrecise Pharmacogenetics program. Pharmacogenetics allows prescribers and pharmacists to understand how medications react differently in the body based on an individual's metabolism. BenePrecise applies the results of a fast and easy-to-administer pharmacogenetics test to enhance member safety, improve treatment outcomes and prevent wasteful drug spending.

BenePrecise utilizes precision medicine, which evaluates and considers a patient's metabolism, environment and lifestyle, to develop effective, individualized treatment plans. Through BenePrecise, BeneCard PBF's pharmacists work with members and their prescribers to coordinate changes in drug therapies, as indicated by pharmacogenetic testing. This ensures that members receive the most clinically appropriate and effective medications. By proactively identifying which drug therapies will not work, or are likely to cause severe adverse reactions, clients and their members can avoid unnecessary risks and expenses.

"We are excited to offer our BenePrecise program," says Jennifer Fuhrmann, PharmD and Vice President of Clinical Services for BeneCard PBF. "Pharmacogenetic testing can have a measurable positive impact for members who live with chronic health challenges such as diabetes or high cholesterol. Our pharmacists can help them move quickly onto the most appropriate drug therapy and improve their health with fewer side effects and less risk, based on their unique metabolism."

There are no doctor's visits required to administer the test. Members can collect and submit the sample from home using a simple cheek swab. The markers identified by pharmacogenetic testing do not change over a member's lifetime, so repeat tests are not required.

BenePrecise enables a personalized approach to care aimed at reducing costs, improving treatment efficacy and preventing adverse drug reactions.                       

About BeneCard PBF
Through pharmacogenetics and proactive clinical programs, BeneCard PBF enhances patient outcomes while lowering prescription drug costs. With offices in Florida, Pennsylvania and New Jersey, BeneCard PBF administers fixed-rate and self-funded prescription benefit programs. The company offers innovative solutions to control costs while providing the highest quality service available in prescription benefit management.

View original content:http://www.prnewswire.com/news-releases/innovative-pbm-introduces-pharmacogenetics-offering-300494187.html

SOURCE BeneCard PBF

Synthetic Biology Market Size is Projected to be Around $26 Billion by 2025: Crystal Market Research

LAS VEGAS, July 26, 2017 /PRNewswire/ --

A research study titled, Synthetic Biology Market by Product (Oligonucleotide Synthesis, DNA Synthesis, Standardized DNA Parts, Synthetic Genes, Chassis Organisms) and Application (Agriculture, Chemicals, Biofuels, Healthcare) - Global Industry Analysis and Forecast to 2025" published by Crystal Market Research, states that the synthetic biology market is projected to be around $26 billion by 2025.

     (Logo: http://mma.prnewswire.com/media/525277/Crystal_Market_Research_Logo.jpg )
Synthetic biology refers to interdisciplinary area used for creating new biological parts, devices, and systems with the help of engineering principles. It can be used to develop bio-products, advanced biofuels, renewable materials, and bio-based specialty chemicals. Synthetic biology can be used to identify and catalog standardized genomic parts which can be synthesized quickly and used to build novel biological systems. In natural product synthesis, synthetic biology can be used to produce necessary enzymes along with biological functions to carry out complex multi-stage production of natural products. In biofuels, synthetic biology can be used for optimization of genes and microorganisms to efficiently convert feedstock into biofuels. Synthetic biology is anticipated to witness adoption in varied industries such as agriculture, energy, pharmaceuticals, and chemicals. In medicine, synthetic biology can be used for manufacturing of drugs, diagnostic agents and vaccines and in creation of new tissues. In chemical industry, synthetic biology can be used in the production of fine or bulk chemicals such as proteins to provide a substitute to existing synthetic fibers or natural fibers.

Browse full research report with TOC on "Synthetic Biology Market by Product and Application - Global Industry Analysis and Forecast to 2025" at: https://www.crystalmarketresearch.com/report/synthetic-biology-market

Reduction in the cost of DNA sequencing, rise in the development of genetically engineered crops, increased research and development related expenditure of biotechnology and pharmaceutical companies, growing demand for synthetic genes are set to drive this market. On the other hand, stringent regulations related to bio-safety & bio-security can restrict the growth of this market.

In 2016, enabled product segment occupied the major share of the global synthetic biology market owing to growing demand for higher-value specialty products. Besides, core product will grow at highest CAGR during the forecast period owing to increasing use of synthetic genes and development of DNA constructs. Healthcare segment occupied the major share of the overall synthetic biology market in 2016 owing to high usage in developing economical drugs and vaccines.

In 2016, Europe occupied the major share of the synthetic biology market owing to rising government funding and increased R&D efforts. On the other hand, Asia-Pacific is projected to witness significant growth in the forecast period.

Strategic collaborations is the key strategy adopted by the leading players in the market. For instance, in May 2017, Oxford Genetics (a leading synthetic biology-based technology company) entered into a non-exclusive licensing agreement with ERS Genomics. This agreement grants Oxford Genetics to access ESR's foundational intellectual property about CRISPR/Cas9 gene editing technology. Similarly, in May 2016, Bayer and ESR Genomics entered into a patent license agreement. As per the terms of agreement, Bayer obtained access to ESR's genome editing patent portfolio (i.e. CRISPR-Cas9) for cross divisional applications in its strategic business areas.

Request a sample copy of Synthetic Biology Market Research Report @ https://www.crystalmarketresearch.com/report-sample/HC06129

Some of the leading players in the global synthetic biology market are New England Biolabs, Inc., Synthetic Genomics Inc., Integrated DNA Technologies, Inc., DuPont,Amyris, Inc., GenScript, Intrexon Corporation, Gingko Bioworks, Thermo Fisher Scientific Inc., Intrexon Corporation, and Agilent Technologies, Inc.

Key Findings of the Research Study:

  • Enabled product segment accounted for the largest share of the overall market in 2016
  • Core product category is poised to be the fastest-growing segment during the forecast period
  • Europe dominated the global market for synthetic biology in 2016 due to increased R&D efforts for the development of synthetic biology products
  • Asia-Pacific is expected to grow at double digit CAGR during the forecast period due to high demand for synthetically manufactured crops and rising awareness about synthetic biology

Inquire more about this report at: https://www.crystalmarketresearch.com/send-an-enquiry/HC06129

Synthetic Biology Market Segmentation: 

By Product: 

- Enabling Products

  • Oligonucleotide Synthesis
  • DNA Synthesis

- Core Products

  • Standardized DNA Parts
  • Synthetic Genes
  • Chassis Organisms

- Enabled Products

By Application: 

  • Agriculture
  • Chemicals
  • Biofuels
  • Healthcare
  • Others

By Region: 

- North America

  • U.S
  • Canada
  • Mexico

- Europe 

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe

- Asia-Pacific

  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific

- Rest of the World 

  • Brazil
  • South Africa
  • Saudi Arabia
  • Turkey
  • United Arab Emirates
  • Others

Get Customization in the Report At: https://www.crystalmarketresearch.com/customization/HC06129

About Crystal Market Research 

Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customized research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy.

Contact:
Judy
304 South Jones Blvd, Suite 1896,
Las Vegas NV 89107,
United States
Toll Free: +1-888-213-4282
Email: sales@crystalmarketresearch.com

Blog: https://blog.crystalmarketresearch.com

Website: http://www.crystalmarketresearch.com

Connect with us: LinkedIn | Twitter | Facebook

CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine

Data from phase I clinical trial of CureVac's RNActive® prophylactic vaccine technology in rabies demonstrates for the first time an induction of boostable functional antibodies against a viral antigen when administered via needle-free injection

TÜBINGEN, Germany, July 26, 2017 /PRNewswire/ -- CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced that the results of CureVac's phase I clinical trial of its RNActive® prophylactic rabies vaccine was published in the peer-reviewed journal The Lancet. The study was the first in-human proof-of-concept clinical trial of a prophylactic mRNA-based vaccine. Subsequently, the mRNA drug substance encoding a rabies virus glycoprotein was given the International Nonproprietary Name (INN) Nadorameran by the World Health Organization (WHO) as first drug substance of this new class.

The paper, titled "Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open label, non-randomized, prospective, first-in-human phase I clinical trial," by Alberer et al., reported results of the phase I clinical trial, which was designed to examine the safety and immunogenicity of CureVac's first-generation RNActive® prophylactic vaccine against rabies, CV7201. Data from the study indicated that CV7201 was generally safe with a reasonable tolerability profile. Importantly the study demonstrated for the first time ever that a prophylactic mRNA-based vaccine candidate can induce boostable functional antibodies against a viral antigen when administered using a needle-free jet injection device.

Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, stated, "We are very pleased to have our pioneering phase I study in rabies published in the renowned journal The Lancet. The data demonstrate the potential of our first generation RNActive® prophylactic vaccine technology to induce immune responses in naïve human subjects. The findings from this study have been instrumental in significantly improving our mRNA technology leading to second generation prophylactic vaccines. We now look forward to continuing a clinical program of our enhanced rabies vaccine in early 2018."

Ulrike Gnad-Vogt, M.D., CMO of CureVac, stated, "While this phase I trial was conducted several years ago and we elected to follow up efficacy and safety for a longer time period, the study is a landmark achievement for CureVac and the mRNA industry as it provided further foundation for understanding mRNA-based vaccines in humans as well as the building blocks for CureVac to develop its next-generation RNActive® technology. On behalf of CureVac, I would like to express my gratitude to the volunteers for participating in the trial, the investigators for their hard work and dedication, and to The Lancet for providing an opportunity to publish this groundbreaking research."

Andrew Farnum, Director of Program-Related Investments at the Bill & Melinda Gates Foundation, stated, "mRNA-based prophylactic vaccines offer the opportunity to address a wide range of infectious diseases, including those that disproportionately affect people in the world's poorest countries. Although there is a need for further research, these results are an important first step towards realizing the potential of CureVac's mRNA vaccine technology. We look forward to continuing our collaboration with CureVac that could potentially provide vulnerable communities with the affordable, life-saving vaccines they need."

The phase I proof-of-concept, open-label, uncontrolled, prospective clinical trial was initiated in a single site – the Department of Infectious Diseases and Tropical Medicine, Medical Centre of the University Hospital of Munich, Germany. From October 2013, the study enrolled 101 healthy adults, with subjects receiving three CV7201 doses either intradermally or intramuscularly by needle-syringe or one of three needle-free devices. Escalating doses were given to subsequent cohorts, and one cohort received a booster dose after one year. Primary endpoints were safety and tolerability, secondary endpoint was the induction of WHO-recommended level of virus neutralizing antibody titers.

About The Lancet

The Lancet began as an independent, international weekly general medical journal founded in 1823 by Thomas Wakley. Since its first issue (October 5, 1823), the journal has strived to make science widely available so that medicine can serve, and transform society, and positively impact the lives of people. Over the past two centuries, The Lancet has sought to address urgent topics in our society, initiate debate, put science into context, and influence decision makers around the world.

About CureVac AG

Founded in 2000 as a spin-off from the University of Tϋbingen in Germany, CureVac is a leading company in the field of mRNA technology and was the first company to start clinical trials on mRNA-based drugs. The biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.

Since its inception, strongly backed by SAP founder Dietmar Hopp's dievini, CureVac has received approximately $370 million (€355 million) in equity investments including an investment of the Bill & Melinda Gates Foundation of $ 52million in 2015. CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.

In 2006, CureVac successfully established the first worldwide GMP facility for the manufacturing of mRNA. In 2017 CureVac started the establishment and construction of industrial scale production facilities.

For more information, please visit www.curevac.com

Media Contacts

Verena Lauterbach, Senior Manager Communications
CureVac AG, Tübingen, Germany
+49 (0) 7071 9883 1756
verena.lauterbach@curevac.com

Janine McCargo, SVP
Tiberend Strategic Advisors, New York
+1 646 604 5150
jmccargo@tiberend.com

View original content:http://www.prnewswire.com/news-releases/curevac-announces-publication-in-the-lancet-of-first-ever-human-proof-of-concept-study-investigating-the-safety-and-immunogenicity-of-a-prophylactic-mrna-vaccine-300494154.html

SOURCE CureVac AG

BioLineRx Announces Additional Investment From BVF Partners L.P.

TEL AVIV, Israel, July 26, 2017 /PRNewswire/ --

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that BVF Partners L.P. (BVF), its largest shareholder, has entered into a definitive agreement to make an additional, direct investment of $9.6 million in BioLineRx, increasing its economic interest in the Company to 24.9%. The sale is expected to close on or about July 31, 2017, subject to satisfaction of customary closing conditions.

BVF's new investment is priced at $1.13 per unit. Each unit consists of 1 ordinary share, 0.35 of a Series A warrant, and 0.35 of a Series B warrant. The Series A warrants have an exercise price of $2.00 per ordinary share and a 4-year term. The Series B warrants have an exercise price of $4.00 per ordinary share and a 4-year term. The securities are being offered pursuant to a prospectus as a registered direct placement.

Mark Lampert, Founder and President of BVF Partners L.P., commented: "BioLineRx's therapeutic pipeline, strategic collaborations, scientific breadth and capabilities provide for a compelling investment opportunity for BVF. We are pleased to support the Company in the continued advancement of its clinical programs."

Philip A. Serlin, Chief Executive Officer of BioLineRx, remarked, "We thank BVF for their support and confidence. BVF's new direct investment, on the heels of its recent initial investment in the Company this past March, provides us with additional resources to accelerate our clinical development programs. We continue to execute on our clinical development strategy and look forward to the data readouts from our multiple clinical studies."

The securities will be issued pursuant to a shelf registration statement that was previously filed with, and declared effective by, the Securities and Exchange Commission ("SEC"). A prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BioLineRx 

BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and is expected to initiate a Phase 3 study in stem cell mobilization for autologous transplantation; and AGI-134, an immunotherapy treatment in development for multiple solid tumors, which is expected to initiate a first-in-man study in the first half of 2018. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates; a collaboration agreement with MSD (known as Merck in the US and Canada), on the basis of which the Company has initiated a Phase 2a study in pancreatic cancer using the combination of BL-8040 and Merck's KEYTRUDA®; and a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 and Genentech's Atezolizumab in several Phase 1b/2 studies for multiple solid tumor indications and AML.

For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2017. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law. 

Contact:
PCG Advisory
Vivian Cervantes
Investor Relations
212-554-5482
vivian@pcgadvisory.com

Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipihai5@gmail.com